12 hours | Primary site of action: extracellular matrix, gene expression | Key receptors: TGF-beta, MMP/TIMP | Research focus: skin regeneration, anti-aging, collagen | Endogenous: yes (plasma component) | Gene modulation: over 4,000 genes BPC-157 Half-life: approx
Address underlying conditions Treatment depends entirely on the identified cause: Liver disease: Management according to aetiology (alcohol cessation, antiviral therapy for hepatitis, treatment of non-alcoholic fatty liver disease)
Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC, Gruetter R
Start with the established compound and consider retatrutide if you plateau or if it gains FDA approval during your treatment
Gut-liver axis: Liver sinusoidal endothelial cells function as the hepatic barrier in colitis-induced liver injury